Dupilumab

Dupilumab (Dupixent) is a human monoclonal antibody against the IL-4 receptor α subunit. It blocks both IL-4 and IL-13 signalling, the core of the Th2 Immune Response in Atopic Dermatitis. In AD skin it restores Filaggrin and loricrin expression, which the placebo did not (Furue 2020). It is given as an injection under the skin. Unlike Systemic Immunosuppressants such as ciclosporin, it does not broadly suppress the immune system. It is the only systemic eczema medicine licensed for children as young as 6 months (Paller, Pediatric Drugs 2026). It is reserved for moderate-to-severe eczema that topical treatment (Topical Corticosteroids, Topical Calcineurin Inhibitors, Emollient Therapy) has not controlled.

Dupilumab [treats] Atopic Dermatitis Dupilumab [opposes] Th2 Immune Response Dupilumab [supports] Filaggrin Dupilumab [relates] Systemic Immunosuppressants

LIBERTY AD PRESCHOOL: the key toddler trial. The LIBERTY AD PRESCHOOL part B trial (Paller et al., Lancet 2022) randomised 162 children aged 6 months to under 6 years with moderate-to-severe AD that Topical Corticosteroids had not controlled. They got dupilumab or placebo every 4 weeks for 16 weeks. Everyone also used hydrocortisone acetate 1% cream. At week 16, 28% on dupilumab had clear or almost-clear skin, against 4% on placebo. 53% reached EASI-75, against 11% on placebo (both p<0.0001). Overall adverse events were similar (64% vs 74%), and no dupilumab-related event was serious. In the open-label extension, 121 children with severe AD were followed for up to 2 years (50 reached week 104). By then 96% had EASI-75 and 92% had clear-to-mild disease, but only 27% were clear or almost clear (Paller, Pediatric Drugs 2026). Both studies were funded by the manufacturers (Sanofi/Regeneron).

LIBERTY AD PRESCHOOL [supports] Dupilumab Dupilumab [relates] EASI Hydrocortisone [part-of] LIBERTY AD PRESCHOOL

Licensing, dosing and cost. The US label covers patients aged 6 months and older with moderate-to-severe AD not controlled by topical prescription therapy (FDA label, 2026). Drugs@FDA lists the efficacy supplement for this age group as approved on 7 June 2022. For 6 months to 5 years there is no loading dose. The dose is 200 mg every 4 weeks for 5–<15 kg, or 300 mg every 4 weeks for 15–<30 kg. The EU licence for children aged 6 months to 11 years covers severe AD only (EMA EPAR). The EMA page does not give the date of the 6-month extension; the task brief’s “2023” was not verified. NICE has no child-specific appraisal. In April 2022 it declined to appraise “dupilumab for children with severe AD” because adult guidance (TA534) exists. NHS England commissions under-18 use where TA534 conditions are met (NICE TSID10434). The TA534 list price was £1,264.89 per pack of two pre-filled syringes (BNF 2018, excl. VAT). That makes it a high-cost specialist medicine, prescribed only in hospital dermatology clinics in the UK.

Conflict: [FDA Dupixent label, 2026] licenses dupilumab from 6 months for moderate-to-severe AD. [EMA Dupixent EPAR, accessed 2026-10-03] licenses it in children 6 months–11 years for severe AD only. Unresolved — add to open_questions.

FDA [regulates] Dupilumab European Medicines Agency [regulates] Dupilumab NICE [regulates] Dupilumab

Side effects and injection burden. The main specific side effect is Conjunctivitis (eye inflammation). In the preschool RCT it affected 5% on dupilumab and none on placebo (Lancet 2022). Over 2 years of open-label use it affected 19% of under-6s. Episodes were mild or moderate, lasted a median of 8 days, and none led to stopping treatment (Paller 2026). The US label also warns of keratitis, blepharitis, oral herpes and other Herpes Simplex Virus infections, injection-site reactions and eosinophilia. Rarely, facial skin reactions and new psoriasis occur. One drug-related pinworm infection and one case of severe urticaria were reported in the 2-year extension. For families the practical burden is a needle every 4 weeks, often given at home by parents after training. This is a real hurdle for needle-anxious toddlers and parents, although it is far less frequent than daily creams.

Eye symptoms on dupilumab

Red, itchy, sore or watery eyes are the most common specific side effect. In the trials most cases were mild, but keratitis (corneal inflammation) is a labelled risk. New eye symptoms in a child on dupilumab should be reported to the prescriber; some need ophthalmology review.

Dupilumab [causes] Conjunctivitis Dupilumab [relates] Herpes Simplex Virus

Long-term data, the atopic march and food allergy. Whether dupilumab can change the Atopic March is an open question. A sponsor meta-analysis of 12 AD trials found fewer new or worsening allergic conditions on dupilumab than on placebo (IRR 0.66; new allergies IRR 0.63) (Geba, JACI 2023). But the median age was 35 and follow-up was at most 52 weeks, so it says little about toddlers. For Food Allergy, a 2026 systematic review found that dupilumab consistently lowers total and food-specific IgE but does not reliably produce tolerance. In a phase II peanut trial, dupilumab alone did not improve Oral Food Challenge results (Grześk-Kaczyńska 2026). There is no preschool trial showing that early dupilumab prevents asthma or food allergy. Safety data in under-6s currently go up to about 2 years.

Dupilumab [relates] Atopic March Dupilumab [relates] Food Allergy Dupilumab [relates] Oral Food Challenge

What parents report (evidence: anecdotal). Parents of toddlers with severe eczema call dupilumab “life changing”. One child started at age 2 alongside tacrolimus, was largely clear within 2 months, “sleeps through the night” and no longer needs topical steroids. A 4-year-old hospitalised with staph was “90 percent cleared” (r/eczema). Parents’ hesitations: the child’s age, monthly injections and insurance prior-authorisation that can take months. A UK parent says it helped after “five years” of creams (Mumsnet). See Parent Experiences.

Dupilumab [relates] Parent Experiences

Licensing update (Oct 2026). The age floor has not changed. The FDA label (effective 22 April 2026) still covers moderate-to-severe AD from 6 months. The European Medicines Agency EPAR (updated 18 August 2026) and the UK SmPC on emc (revised 17 June 2026) still cover only severe AD in children aged 6 months to 11 years. No licence below 6 months was found. The AAD Pediatric Guideline 2026 now strongly recommends dupilumab from 6 months for moderate-to-severe AD. It notes that data are thinner for 6 months to 2 years and suggests spacing doses 4-weekly to reduce the trauma of injections. The other eczema biologics are still licensed only from age 12 on the FDA, EMA and UK labels: tralokinumab (Adbry/Adtralza), lebrikizumab (Ebglyss; at least 40 kg) and nemolizumab (Nemluvio; with topical therapy, and at least 30 kg in the UK). So dupilumab is still the only biologic licensed for 1–4-year-olds.

AAD Pediatric Guideline 2026 [supports] Dupilumab

Connections

• Th2 Immune Response — blocks IL-4/IL-13 via IL-4Rα, source: Furue 2020
• Filaggrin — restores FLG/loricrin expression, source: Furue 2020
• LIBERTY AD PRESCHOOL — pivotal 6 mo–5 y RCT, source: Paller Lancet 2022
• Atopic Dermatitis — treats moderate-to-severe disease, source: FDA label 2026; EMA EPAR
• Conjunctivitis — main specific adverse effect (5% RCT, 19% at 2 y), source: Paller 2022/2026
• Atopic March — possible attenuation, adult-dominated data, source: Geba JACI 2023
• Food Allergy — lowers IgE, no proven tolerance, source: Grześk-Kaczyńska 2026
• Systemic Immunosuppressants — alternative/earlier systemic option, source: Flohr BJD 2023
• JAK Inhibitors — other advanced systemic class; oral JAKs mostly ≥12 y, source: FDA/EMA labels
• NICE — no child TA; NHS England commissions via TA534, source: NICE TSID10434
• European Medicines Agency — EU severe-only 6 mo–11 y licence, source: EMA EPAR
• FDA — US 6 mo+ moderate-to-severe licence (2022), source: FDA label / Drugs@FDA
• Tree Nut Allergy — tree-nut sIgE fell 70–82% in paediatric AD on dupilumab, source: Nutrients 2024 review
• SAHPRA — SA-registered for AD only from 6 years (PIL May 2024); toddler use off-label in SA, source: SAHPRA Dupixent PIL 2024
• South African Eczema Guidance — biologics out of reach of most SSA public systems, source: ISAD 2019
• Cost of Eczema Care — £1,264.89 per 2 syringes list price, source: BNF 2018
• Parent Experiences — parent reports (anecdotal), source: round-10 forum threads
• AAD Pediatric Guideline 2026 — strong rec ≥6 months; consider 4-weekly spacing, source: JAAD 2026; licences re-checked Oct 2026